Immune modulations of the tumor microenvironment in response to phototherapy

Trisha I. Valerio; Coline L. Furrer; Negar Sadeghipour; Sophia-Joy X. Patrock; Sayre A. Tillery; Ashley R. Hoover; Kaili Liu; Wei R. Chen

doi:10.1142/S1793545823300070

Journal of Innovative Optical Health Sciences, Volume. 16, Issue 3, 2330007(2023)

Immune modulations of the tumor microenvironment in response to phototherapy

Trisha I. Valerio1... Coline L. Furrer1, Negar Sadeghipour1,2, Sophia-Joy X. Patrock1, Sayre A. Tillery1, Ashley R. Hoover1, Kaili Liu1 and Wei R. Chen1,* |Show fewer author(s)

Author Affiliations

¹Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, Oklahoma 73019, USA

²School of Electrical and Computer Engineering, University of Oklahoma, Norman, Oklahoma 73019, USA

show less

References(151)

[2] The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 127, 3029-3030(2021). https://doi.org/10.1002/cncr.33587

[3] On the origin of cancer metastasis. Crit. Rev. Oncogenesis, 18, 43-73(2013). https://doi.org/10.1615/critrevoncog.v18.i1-2.40

[4] The lingering mysteries of metastatic recurrence in breast cancer. Br. J. Cancer, 124, 13-26(2021). https://doi.org/10.1038/s41416-020-01161-4

[5] Drug resistance in cancer: An overview. Cancers, 6, 1769-1792(2014). https://doi.org/10.3390/cancers6031769

[6] The different mechanisms of cancer drug resistance: A brief review. Adv. Pharm. Bull., 7, 339-348(2017). https://doi.org/10.15171/apb.2017.041

[7] Assessment of the evolution of cancer treatment therapies. Cancers, 3, 3279-3330(2011). https://doi.org/10.3390/cancers3033279

[8] Combination therapy in combating cancer. Oncotarget, 8, 38022-38043(2017). https://doi.org/10.18632/oncotarget.16723

[9] The most common side effects experienced by patients were receiving first cycle of chemotherapy. Iran. J. Public Health, 47, 1218-1219(2018).

[10] Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, N.Y.), 313, 1960-1964(2006). https://doi.org/10.1126/science.1129139

[11] The tumor microenvironment at a glance. J. Cell Sci., 125, 5591-5596(2012). https://doi.org/10.1242/jcs.116392

[12] Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. J. Cell. Biochem., 101, 937-949(2007). https://doi.org/10.1002/jcb.21187

[13] Association between tumor-stroma ratio and prognosis in solid tumor patients: A systematic review and meta-analysis. Oncotarget, 7, 68954-68965(2016). https://doi.org/10.18632/oncotarget.12135

[14] Strategies for delivering nanoparticles across tumor blood vessels. Adv. Funct. Mater., 31, 2007363(2021). https://doi.org/10.1002/adfm.202007363

[15] A review of the development of tumor vasculature and its effects on the tumor microenvironment. Hypoxia (Auckland, N.Z.), 5, 21-32(2017). https://doi.org/10.2147/HP.S133231

[16] An overview of the tumor microenvironment, from cells to complex networks (Review). Exp. Ther. Med., 21, 96(2021). https://doi.org/10.3892/etm.2020.9528

[17] Cancer-associated fibroblasts: Overview, progress, challenges, and directions. Cancer Gene Ther., 28, 984-999(2021). https://doi.org/10.1038/s41417-021-00318-4

[18] Hypoxia and the tumor microenvironment. Technol. Cancer Res. Treat., 20, 15330338211036304(2021). https://doi.org/10.1177/15330338211036304

[19] Cancer stem cells and the tumor microenvironment in gastric cancer. Front. Oncol., 11, 803974(2022). https://doi.org/10.3389/fonc.2021.803974

[20] Tumor endothelial cells. Cold Spring Harbor Perspect. Med., 2, a006536(2012). https://doi.org/10.1101/cshperspect.a006536

[21] Adipocytes in the tumour microenvironment. Adv. Exp. Med. Biol., 1234, 1-13(2020). https://doi.org/10.1007/978-3-030-37184-5_1

[22] The emerging roles of pericytes in modulating tumor microenvironment. Front. Cell Dev. Biol., 9, 676342(2021). https://doi.org/10.3389/fcell.2021.676342

[23] The tumor microenvironment and its role in promoting tumor growth. Oncogene, 27, 5904-5912(2008). https://doi.org/10.1038/onc.2008.271

[24] The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct. Target. Ther., 5, 166(2020). https://doi.org/10.1038/s41392-020-00280-x

[25] The tumor microenvironment. Curr. Biol., 30, R921-R925(2020). https://doi.org/10.1016/j.cub.2020.06.081

[26] Nano-ablative immunotherapy for cancer treatment. Nanophotonics, 10, 3247-3266(2021). https://doi.org/10.1515/nanoph-2021-0171

[27] Single-cell-based computer simulation of the oxygen-dependent tumour response to irradiation. Phys. Med. Biol., 52, 4775-4789(2007). https://doi.org/10.1088/0031-9155/52/16/005

[28] Modeling and computer simulations of tumor growth and tumor response to radiotherapy. Radiat. Res., 162, 71-83(2004). https://doi.org/10.1667/rr3193

[29] The clinical role of the TME in solid cancer. Br. J. Cancer, 120, 45-53(2019). https://doi.org/10.1038/s41416-018-0327-z

[30] How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies: Helping nonimmunologists decipher recent advances. Oncol., 21, 233-243(2016). https://doi.org/10.1634/theoncologist.2015-0282

[31] Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br. J. Cancer, 97, 952-956(2007). https://doi.org/10.1038/sj.bjc.6603962

[32] Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J. Oral Pathol. Med., 32, 195-199(2003). https://doi.org/10.1034/j.1600-0714.2003.00128.x

[33] Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest., 33, 420-425(2003). https://doi.org/10.1046/j.1365-2362.2003.01152.x

[34] A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer, 20, 174-186(2020). https://doi.org/10.1038/s41568-019-0238-1

[35] Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res., 21, 687-692(2015). https://doi.org/10.1158/1078-0432.CCR-14-1860

[36] Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int. Immunol., 28, 383-391(2016). https://doi.org/10.1093/intimm/dxw014

[37] Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): A population-based study. Lancet Oncol., 20, 1493-1505(2019). https://doi.org/10.1016/S1470-2045(19)30456-5

[38] Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal., 18, 59(2020). https://doi.org/10.1186/s12964-020-0530-4

[39] Multiscale computational modeling of cancer growth using features derived from microCT images. Sci. Rep., 11, 18524(2021). https://doi.org/10.1038/s41598-021-97966-1

[40] Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol., 3, 991-998(2002). https://doi.org/10.1038/ni1102-991

[41] Therapy-induced modulation of the tumor microenvironment: New opportunities for cancer therapies. Front. Oncol., 10, 582884(2020). https://doi.org/10.3389/fonc. 2020.582884

[42] The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets. BMB Rep., 54, 31-43(2021). https://doi.org/10.5483/BMBRep.2021.54.1.224

[43] Dendritic cell biology and its role in tumor immunotherapy. J. Hematol. Oncol., 13, 107(2020). https://doi.org/10.1186/s13045-020-00939-6

[44] Origin and functions of tissue macrophages. Immunity, 41, 21-35(2014). https://doi.org/10.1016/j.immuni.2014.06.013

[45] Diverse macrophages polarization in tumor microenvironment. Arch. Pharmacal Res., 39, 1588-1596(2016). https://doi.org/10.1007/s12272-016-0820-y

[46] Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. Sci. Rep., 10, 6096(2020). https://doi.org/10.1038/s41598-020-63276-1

[47] Tumor-infiltrating lymphocytes in the immunotherapy era. Cell. Mol. Immunol., 18, 842-859(2021). https://doi.org/10.1038/s41423-020-00565-9

[48] Tumor infiltrating lymphocytes: The regulator of melanoma evolution. Oncol. Lett., 17, 4155-4161(2019). https://doi.org/10.3892/ol.2019.9940

[49] Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br. J. Cancer, 124, 359-367(2021). https://doi.org/10.1038/s41416-020-01048-4

[50] T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature, 427, 154-159(2004). https://doi.org/10.1038/nature02238

[51] Dendritic cells and CD8 T cell immunity in tumor microenvironment. Front. Immunol., 9, 3059(2018). https://doi.org/10.3389/fimmu.2018.03059

[52] CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review. J. Cell. Physiol., 234, 8509-8521(2019). https://doi.org/10.1002/jcp.27782

[53] The outstanding antitumor capacity of CD4+ T helper lymphocytes. Biochim. et Biophys. Acta Rev. Cancer, 1874, 188439(2020). https://doi.org/10.1016/j.bbcan.2020.188439

[54] The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell. Mol. Immunol., 7, 182-189(2010). https://doi.org/10.1038/cmi.2010.22

[55] CD4 T-cell subsets and tumor immunity: The helpful and the not-so-helpful. Cancer Immunol. Res., 2, 91-98(2014). https://doi.org/10.1158/2326-6066.CIR-13-0216

[56] Modulation of CD4 T cell response according to tumor cytokine microenvironment. Cancers, 13, 373(2021). https://doi.org/10.3390/cancers13030373

[57] Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol., 179, 37-45(2011). https://doi.org/10.1016/j.ajpath.2011.03.007

[58] CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest., 123, 2873-2892(2013). https://doi.org/10.1172/JCI67428

[59] Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci., 110, 2080-2089(2019). https://doi.org/10.1111/cas.14069

[60] T regulatory cells and priming the suppressive tumor microenvironment. Front. Immunol., 10, 2453(2019). https://doi.org/10.3389/fimmu.2019.02453

[61] Regulatory T cells exhibit distinct features in human breast cancer. Immunity, 45, 1122-1134(2016). https://doi.org/10.1016/j.immuni.2016.10.032

[62] Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight, 5, e129641(2019). https://doi.org/10.1172/jci.insight.129641

[63] Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int. J. Cancer, 139, 1129-1139(2016). https://doi.org/10.1002/ijc.30138

[64] Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity, 52, 183-199.e9(2020). https://doi.org/10.1016/j.immuni.2019.11.014

[65] Depleting tumor infiltrating B cells to boost antitumor immunity with tumor immune-microenvironment reshaped hybrid nanocage. ACS Nano, 16, 4263-4277(2022). https://doi.org/10.1021/acsnano.1c10283

[66] Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer, 22, 557-575(2022). https://doi.org/10.1038/s41568-022-00491-0

[67] Tailoring natural killer cell immunotherapy to the tumour microenvironment. Semin. Immunol., 31, 30-36(2017). https://doi.org/10.1016/j.smim.2017.09.001

[68] A review of cancer immunotherapy: From the past, to the present, to the future. Curr. Oncol., 27, S87-S97(2020). https://doi.org/10.3747/co.27.5223

[69] Immunotherapy: Enhancing the efficacy of this promising therapeutic in multiple cancers. Clin. Sci., 133, 181-193(2019). https://doi.org/10.1042/CS20181003

[70] Cancer immunotherapy. Cancer Biother. Radiopharm., 26, 1-64(2011). https://doi.org/10.1089/cbr.2010.0902

[71] Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics, 6, 762-772(2016). https://doi.org/10.7150/thno.14988

[72] Update on laser photochemotherapy: An alternative for cancer treatment. Anti-Cancer Agents Med. Chem., 11, 772-779(2011). https://doi.org/10.2174/187152011797378742

[73] Photodynamic therapy of cancer: An update. CA: Cancer J. Clin., 61, 250-281(2011). https://doi.org/10.3322/caac.20114

[74] Photosensitizers for photodynamic therapy. Adv. Healthcare Mater., 8, e1900132(2019). https://doi.org/10.1002/adhm.201900132

[75] Photodynamic therapy and anti-tumor immunity. Lasers Surg. Med., 38, 509-515(2006). https://doi.org/10.1002/lsm.20362

[76] Nanoscale covalent organic polymers as a biodegradable nanomedicine for chemotherapy-enhanced photodynamic therapy of cancer. Nano Res., 11, 3244-3257(2018). https://doi.org/10.1007/s12274-017-1858-y

[77] Advances in nanomaterial-mediated photothermal cancer therapies: Toward clinical applications. Biomedicines, 9, 305(2021). https://doi.org/10.3390/biomedicines9030305

[78] Recent progress in cancer thermal therapy using gold nanoparticles. J. Phys. Chem. C, 120, 4691-4716(2016).

[79] Nanomaterials as photothermal therapeutic agents. Prog. Mater. Sci., 99, 1-26(2019). https://doi.org/10.1016/j.pmatsci.2018.07.005

[80] Photothermal therapy-induced immunogenic cell death based on natural melanin nanoparticles against breast cancer. Chem. Commun., 56, 1389-1392(2020). https://doi.org/10.1039/c9cc08447a

[81] Nanomaterial-based tumor photothermal immunotherapy. Int. J. Nanomed., 15, 9159-9180(2020). https://doi.org/10.2147/IJN.S249252

[82] Molecularly targeted photothermal ablation improves tumor specificity and immune modulation in a rat model of hepatocellular carcinoma. Commun. Biol., 3, 783(2020). https://doi.org/10.1038/s42003-020-01522-y

[83] Nanomaterial applications in photothermal therapy for cancer. Materials (Basel, Switzerland), 12, 779(2019). https://doi.org/10.3390/ma12050779

[84] Advances in nanomaterials for use in photothermal and photodynamic therapeutics (Review). Mol. Med. Rep., 20, 5-15(2019). https://doi.org/10.3892/mmr.2019.10218

[85] Thermal dose as a universal tool to evaluate nanoparticle-induced photothermal therapy. Int. J. Pharm., 587, 119657(2020). https://doi.org/10.1016/j.ijpharm.2020.119657

[86] Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat. Rev. Clin. Oncol., 17, 657-674(2020). https://doi.org/10.1038/s41571-020-0410-2

[87] Neutrophil infiltration and whole-cell vaccine elicited by N-dihydrogalactochitosan combined with NIR phototherapy to enhance antitumor immune response and T cell immune memory. Theranostics, 10, 1814-1832(2020). https://doi.org/10.7150/thno.38515

[88] Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing. Clin. Transl. Med., 12, e937(2022). https://doi.org/10.1002/ctm2.937

[89] Antigen presentation and interferon signatures in B cells driven by localized ablative cancer immunotherapy correlate with extended survival. Theranostics, 12, 639-656(2022). https://doi.org/10.7150/thno.65773

[90] Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol., 16, 71(2018). https://doi.org/10.1186/s12951-018-0392-8

[91] Smart nanoparticles for drug delivery application: Development of versatile nanocarrier platforms in biotechnology and nanomedicine. J. Nanomater., 2019, 3702518, 26(2019). https://doi.org/10.1155/2019/3702518

[92] Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv. Sci., 9, e2103836(2022). https://doi.org/10.1002/advs.202103836

[93] Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. Acta Pharm. Sin. B, 10, 2110-2124(2020). https://doi.org/10.1016/j.apsb.2020.05.008

[94] Modulating the tumor microenvironment to enhance tumor nanomedicine delivery. Front. Pharmacol., 8, 952(2017). https://doi.org/10.3389/fphar.2017.00952

[95] Mechanism of laser immunotherapy: Role of immunoadjuvant and selective photothermal laser-tissue interaction. Int. Workshop Photon. Imag. Biol. Med., 4536, 82-89(2002). https://doi.org/10.1117/12.462529

[96] Nanoparticle-based photothermal and photodynamic immunotherapy for tumor treatment. Int. J. Cancer, 143, 3050-3060(2018). https://doi.org/10.1002/ijc.31717

[97] A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat. Rev. Immunol., 20, 651-668(2020). https://doi.org/10.1038/s41577-020-0306-5

[98] Targeted cancer therapies. Am. Fam. Physician, 103, 155-163(2021).

[99] Multifunctional receptor-targeting antibodies for cancer therapy. Lancet Oncol., 16, e543-e554(2015). https://doi.org/10.1016/S1470-2045(15)00039-X

[100] Therapeutic cancer vaccines. Nat. Rev. Cancer, 21, 360-378(2021). https://doi.org/10.1038/s41568-021-00346-0

[101] Cancer vaccines. Hematol./Oncol. Clin. North America, 33, 199-214(2019). https://doi.org/10.1016/j.hoc.2018.12.001

[102] Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, N.Y.), 348, 62-68(2015). https://doi.org/10.1126/science.aaa4967

[103] Oncolytic virus therapy in cancer: A current review. World J. Virol., 10, 229-255(2021). https://doi.org/10.5501/wjv.v10.i5.229

[104] Immune checkpoint inhibitors in cancer therapy. Curr. Oncol., 29, 3044-3060(2022). https://doi.org/10.3390/curroncol29050247

[105] Cytokines in clinical cancer immunotherapy. Br. J. Cancer, 120, 6-15(2019). https://doi.org/10.1038/s41416-018-0328-y

[106] Use of adjuvants for immunotherapy. Hum. Vaccines Immunother., 13, 1774-1777(2017). https://doi.org/10.1080/21645515.2017.1321725

[107] InCVAX–a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Cancer Lett., 359, 169-177(2015). https://doi.org/10.1016/j.canlet.2015.01.029

[108] Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. New Engl. J. Med., 385, 1856-1867(2021). https://doi.org/10.1056/NEJMoa2112435

[109] Pembrolizumab (Keytruda). Hum. Vaccines Immunother., 12, 2777-2789(2016). https://doi.org/10.1080/21645515.2016.1199310

[110] Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J. Cancer, 8, 410-416(2017). https://doi.org/10.7150/jca.17144

[111] Nivolumab. Drugs Today, 50, 791-802(2014). https://doi.org/10.1358/dot.2014.50.12.2235103

[112] Tremelimumab: A review of development to date in solid tumors. Immunotherapy, 5, 215-229(2013). https://doi.org/10.2217/imt.13.9

[113] Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncol, 12, 873-883(2007). https://doi.org/10.1634/theoncologist.12-7-873

[114] Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol. Res., 65, 9-22(2012). https://doi.org/10.1016/j.phrs.2011.09.002

[115] The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. World Journal of Surgical Oncology, 18, 150(2020). https://doi.org/10.1186/s12957-020-01933-5

[116] Product review: Avelumab, an anti-PD-L1 antibody. Hum. Vaccin. Immunother., 15, 891-908(2019). https://doi.org/10.1080/21645515.2018.1551671

[117] Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. New Engl. J. Med., 383, 1218-1230(2020). https://doi.org/10.1056/NEJMoa2002788

[118] Durvalumab in cancer medicine: A comprehensive review. Expert Opin. Biol. Ther., 19, 927-935(2019). https://doi.org/10.1080/14712598.2019.1635115

[119] Durvalumab for the treatment of non-small cell lung cancer. Expert Rev. Respir. Med., 12, 627-639(2018). https://doi.org/10.1080/17476348.2018.1494575

[120] Cancer immunotherapy using checkpoint blockade. Science (New York, N.Y.), 359, 1350-1355(2018). https://doi.org/10.1126/science.aar4060

[121] Immune checkpoint inhibitor toxicities. Mayo Clin. Proc., 94, 1321-1329(2019). https://doi.org/10.1016/j.mayocp.2019.03.012

[122] Setting the scene — a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy. Rheumatology (Oxford, England), 58, vii1-vii6(2019). https://doi.org/10.1093/rheumatology/kez402

[123] Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer, 118, 9-16(2018). https://doi.org/10.1038/bjc.2017.434

[124] Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 184, 5309-5337(2021). https://doi.org/10.1016/j.cell.2021.09.020

[125] Acquired resistance to immune checkpoint inhibitors. Cancer Cell, 37, 443-455(2020). https://doi.org/10.1016/j.ccell.2020.03.017

[126] The determinants of tumour immunogenicity. Nat. Rev. Cancer, 12, 307-313(2012). https://doi.org/10.1038/nrc3246

[127] Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. eLife, 8, e49020(2019). https://doi.org/10.7554/eLife.49020

[128] Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma. Front. Immunol., 13, 960738(2022). https://doi.org/10.3389/fimmu.2022.960738

[129] Distinguishable prognostic signatures and tumor immunogenicity between pancreatic head cancer and pancreatic body/tail cancer. Front. Oncol., 12, 890715(2022). https://doi.org/10.3389/fonc.2022.890715

[130] Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung J. Med. Sci., 37, 448-458(2021). https://doi.org/10.1002/kjm2.12375

[131] Next generation of immune checkpoint therapy in cancer: New developments and challenges. J. Hematol. Oncol., 11, 39(2018). https://doi.org/10.1186/s13045-018-0582-8

[132] Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nat. Commun., 10, 4871(2019). https://doi.org/10.1038/s41467-019-12771-9

[133] Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. Nanomed., 15, 77-92(2020). https://doi.org/10.2217/nnm-2019-0190

[134] CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J., 11, 69(2021). https://doi.org/10.1038/s41408-021-00459-7

[135] Risks and benefits of chimeric antigen receptor T-cell (CAR-T) Therapy in cancer: A systematic review and meta-analysis. Transfus. Med. Rev., 33, 98-110(2019). https://doi.org/10.1016/j.tmrv.2019.01.005

[136] Advances in universal CAR-T cell therapy. Front. Immunol., 12, 744823(2021). https://doi.org/10.3389/fimmu.2021.744823

[137] Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells. Adv. Mater. (Deerfield Beach, Fla.), 31, e1900192(2019). https://doi.org/10.1002/adma.201900192

[138] Myeloid-derived suppressor cell membrane-coated magnetic nanoparticles for cancer theranostics by inducing macrophage polarization and synergizing immunogenic cell death. Adv. Funct. Mater., 28, 1801389(2018). https://doi.org/10.1002/adfm.201801389

[139] Tumor microenvironment-triggered nanosystems as dual-relief tumor hypoxia immunomodulators for enhanced phototherapy. Theranostics, 10, 9132-9152(2020). https://doi.org/10.7150/thno.46076

[140] Enhanced systemic antilymphoma immune response by photothermal therapy with CpG deoxynucleotide-coated nanoparticles. Blood Adv., 6, 4581-4592(2022). https://doi.org/10.1182/bloodadvances.2022008040

[141] Local phototherapy synergizes with immunoadjuvant for treatment of pancreatic cancer through induced immunogenic tumor vaccine. Clin. Cancer Res., 24, 5335-5346(2018). https://doi.org/10.1158/1078-0432.CCR-18-1126

[142] Nanoscale reduced graphene oxide-mediated photothermal therapy together with IDO inhibition and PD-L1 blockade synergistically promote antitumor immunity. ACS Appl. Mater. Interfaces, 11, 1876-1885(2019). https://doi.org/10.1021/acsami.8b18751

[143] Phototheranostic metal-phenolic networks with antiexosomal PD-L1 enhanced ferroptosis for synergistic immunotherapy. J. Am. Chem. Soc., 144, 787-797(2022). https://doi.org/10.1021/jacs.1c09753

[144] Phototherapy facilitates tumor recruitment and activation of natural killer T cells for potent cancer immunotherapy. Nano Lett., 21, 6304-6313(2021). https://doi.org/10.1021/acs.nanolett.1c02238

[145] Light-triggered multifunctional nanoplatform for efficient cancer photo-immunotherapy. J. Nanobiotechnol., 20, 181(2022). https://doi.org/10.1186/s12951-022-01388-8

[146] New insights into tumor-infiltrating B lymphocytes in breast cancer: Clinical impacts and regulatory mechanisms. Front. Immunol., 9, 470(2018). https://doi.org/10.3389/fimmu.2018.00470

[147] B lymphocytes and cancer: A love-hate relationship. Trends Cancer, 2, 747-757(2016). https://doi.org/10.1016/j.trecan.2016.10.010

[148] The regulatory role of B cells in autoimmunity, infections and cancer: Perspectives beyond IL10 production. FEBS Lett., 589, 3362-3369(2015). https://doi.org/10.1016/j.febslet.2015.08.048

[149] Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med., 189, 832-844(2014). https://doi.org/10.1164/rccm.201309-1611OC

[150] B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunol. Immunother., 62, 87-99(2013). https://doi.org/10.1007/s00262-012-1313-6

[151] Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res., 17, 4987-4995(2011). https://doi.org/10.1158/1078-0432.CCR-11-0207

[152] B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology, 2, e25443(2013). https://doi.org/10.4161/onci.25443

Tools

Get Citation

Copy Citation Text

Trisha I. Valerio, Coline L. Furrer, Negar Sadeghipour, Sophia-Joy X. Patrock, Sayre A. Tillery, Ashley R. Hoover, Kaili Liu, Wei R. Chen. Immune modulations of the tumor microenvironment in response to phototherapy[J]. Journal of Innovative Optical Health Sciences, 2023, 16(3): 2330007

Download Citation

EndNote(RIS)BibTex Plain Text

Set citation alerts for article

Save article for my favorites

Paper Information

Category: Research Articles

Received: Dec. 10, 2022

Accepted: Mar. 19, 2023

Published Online: May. 25, 2023

The Author Email: Chen Wei R. (wei-r-chen@ou.edu)

DOI:10.1142/S1793545823300070

Topics

laser devices and laser physics

Lasers and Laser Optics

Laser physics

laser manufacturing

Instrumentation, Measurement and Metrology

微信扫一扫：分享